RxSight (RXST) Stock Price Target 2026

The average analyst price target for RxSight is $9.23, 103.3% above the current price. Of 9 analysts, 2 rate it Buy, 5 Hold and 2 Sell. Targets range from $5.50 to $28. The latest change came on Nov 4, 2026, when Piper Sandler lowered its price target on RxSight from $10 to $8 and kept a Neutral rating.

The Average Analyst Price Target for RxSight is $9.23.

Price Target Range — 13 Quarters

Analyst Consensus — 9 Analysts

2Buy

5Hold

2Sell

Consensus RatingHold# Analysts9Avg. Consensus PT$9.23Upside to Avg. PT+103.3%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for RxSight Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 4, 2026	Piper Sandler	Adam Maeder	PT Cut	Neutral	$10→$8
Nov 4, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$9→$6
Nov 4, 2026	Needham	David Saxon	PT Cut	Buy	$11→$7
Sep 22, 2026	Jefferies	Young Li	PT Cut	Hold	$7→$6
Sep 22, 2026	B of A Securities	Craig Bijou	PT Cut	Underperform	$7→$6
Aug 10, 2026	Stifel	Tom Stephan	PT Cut	Hold	$8→$7
Aug 6, 2026	UBS	Patrick Wood	PT Raise	Neutral	$6→$6
Jul 28, 2026	UBS	Patrick Wood	Assumes	Neutral	$9→$6
Jul 7, 2026	B of A Securities	Craig Bijou	PT Cut	Underperform	$8→$7
Jul 7, 2026	Needham	David Saxon	Maintained	Buy	$11
May 7, 2026	Wells Fargo	Larry Biegelsen	PT Cut	Equal-Weight	$11→$9
May 7, 2026	Needham	David Saxon	PT Cut	Buy	$13→$11
Mar 9, 2026	Stifel	Tom Stephan	PT Cut	Hold	$10→$9
Feb 26, 2026	UBS	Danielle Antalffy	PT Raise	Neutral	$8→$9
Feb 26, 2026	Piper Sandler	Adam Maeder	PT Cut	Neutral	$11→$10
Feb 26, 2026	Needham	David Saxon	Maintained	Buy	$13
Jan 20, 2026	Piper Sandler	Adam Maeder	PT Raise	Neutral	$10→$11
Dec 2, 2025	Morgan Stanley	Patrick Wood	PT Raise	Equal-Weight	$9→$10
Nov 6, 2025	JP Morgan	Robbie Marcus	PT Raise	Underweight	$8→$9
Nov 6, 2025	Wells Fargo	Larry Biegelsen	PT Raise	Equal-Weight	$9→$10